Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study.

In 30 seconds

This phase I/II clinical trial evaluated intratumoral sotigalimab, a CD40 agonist, plus pembrolizumab in 32 patients with immune-checkpoint-blocker-naïve metastatic melanoma. The combination was reported as well tolerated. At the recommended phase II dose, the objective response rate was 50% and the disease control rate was 92%; response rates were 67% in injected tumors and 50% in non-injected tumors. Tumor and blood analyses showed CD40-pathway engagement and immune activation, including cytotoxic responses in non-injected tumors. Clinical responses correlated with these immune changes, but not with baseline features associated with anti-PD-1 monotherapy response.

Key findings

• At the recommended phase II dose, objective response rate was 50% and disease control rate was 92%.
• Objective response rates were 67% in injected tumors and 50% in non-injected tumors.
• Sotigalimab engaged the CD40 pathway and increased infiltration and activation of myeloid cells, including dendritic cells and macrophages.
• T-cell clonality increased, with new expanded clones shared across tumors; clinical responses correlated with immune changes.

Why it matters

The findings suggest that intratumoral CD40 stimulation alongside PD-1 blockade can be associated with immune activation beyond the injected lesion, an important consideration in metastatic disease. The observed responses and immune changes provide a rationale for further evaluation of this combination, while the early-phase design means the results do not establish comparative benefit over pembrolizumab alone.

What to keep in mind

This was a phase I/II study in 32 patients, and the abstract supports further randomized phase II trials rather than establishing comparative efficacy.